These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 8385161)

  • 1. Pharmacokinetics, safety, and pharmacologic effects of OPC-21268, a nonpeptide orally active vasopressin V1 receptor antagonist, in humans.
    Ohnishi A; Ko Y; Fujihara H; Miyamoto G; Okada K; Odomi M
    J Clin Pharmacol; 1993 Mar; 33(3):230-8. PubMed ID: 8385161
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blood pressure-lowering effect of an orally active vasopressin V1 receptor antagonist in mineralocorticoid hypertension in the rat.
    Burrell LM; Phillips PA; Stephenson JM; Risvanis J; Rolls KA; Johnston CI
    Hypertension; 1994 Jun; 23(6 Pt 1):737-43. PubMed ID: 8206571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of OPC-21268, an orally effective vasopressin V1 receptor antagonist in humans.
    Imaizumi T; Harada S; Hirooka Y; Masaki H; Momohara M; Takeshita A
    Hypertension; 1992 Jul; 20(1):54-8. PubMed ID: 1319959
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety, tolerability, and pharmacokinetics of SR 49059, a V1a vasopressin receptor antagonist, after repeated oral administration in healthy volunteers.
    Brouard R; Laporte V; Serradeil Le Gal C; Pignol R; Jang H; Donat F; Lockwood G; Fournie D; Dreux F
    Adv Exp Med Biol; 1998; 449():455-65. PubMed ID: 10026839
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of vasopressin in essential hypertension. Plasma levels and effects of the V1 receptor antagonist OPC-21268 during different dietary sodium intakes.
    Kawano Y; Matsuoka H; Nishikimi T; Takishita S; Omae T
    Am J Hypertens; 1997 Nov; 10(11):1240-4. PubMed ID: 9397242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of vasopressin V1- and V2-receptor antagonists on hemodynamics in early and late phase after myocardial infarction in rats.
    Fujita H; Yoshiyama M; Takeuchi K; Omura T; Yamagishi H; Iwao H; Miura K; Yoshikawa J
    Jpn J Pharmacol; 1998 Oct; 78(2):229-32. PubMed ID: 9829627
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of a novel orally effective V1-receptor antagonist, OPC-21268, on AVP-induced sympathoinhibition.
    Masaki H; Imaizumi T; Harada S; Momohara M; Hirooka Y; Takeshita A
    Am J Physiol; 1993 Jun; 264(6 Pt 2):R1089-94. PubMed ID: 8391757
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of long-term treatment with selective vasopressin V1 and V2 receptor antagonist on the development of heart failure in rats.
    Nishikimi T; Kawano Y; Saito Y; Matsuoka H
    J Cardiovasc Pharmacol; 1996 Feb; 27(2):275-82. PubMed ID: 8720428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of an orally active vasopressin V1 receptor antagonist.
    Burrell LM; Phillips PA; Stephenson J; Risvanis J; Hutchins AM; Johnston CI
    Clin Exp Pharmacol Physiol; 1993 May; 20(5):388-91. PubMed ID: 8391950
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vascular responses to vasopressin antagonists in man and rat.
    Burrell LM; Phillips PA; Rolls KA; Buxton BF; Johnston CI; Liu JJ
    Clin Sci (Lond); 1994 Oct; 87(4):389-95. PubMed ID: 7834989
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of brain edema with a nonpeptide arginine vasopressin V1 receptor antagonist OPC-21268 in rats.
    Bemana I; Nagao S
    Neurosurgery; 1999 Jan; 44(1):148-54; discussion 154-5. PubMed ID: 9894975
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of a novel non-peptide vasopressin V1 receptor antagonist (OPC-21268) in the rat.
    Burrell LM; Phillips PA; Stephenson J; Risvanis J; Hutchins AM; Johnston CI
    J Endocrinol; 1993 Aug; 138(2):259-66. PubMed ID: 8228734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of an oral vasopressin receptor antagonist (OPC-31260) in a dog with syndrome of inappropriate secretion of antidiuretic hormone.
    Fleeman LM; Irwin PJ; Phillips PA; West J
    Aust Vet J; 2000 Dec; 78(12):825-30. PubMed ID: 11194468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of vasopressin action in vascular smooth muscle by the V1 antagonist OPC-21268.
    Li X; Kribben A; Wieder ED; Tsai P; Nemenoff RA; Schrier RW
    Hypertension; 1994 Feb; 23(2):217-22. PubMed ID: 8307632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Orally active, nonpeptide vasopressin V1 antagonists. A novel series of 1-(1-substituted 4-piperidyl)-3,4-dihdyro-2(1H)-quinolinone.
    Ogawa H; Yamamura Y; Miyamoto H; Kondo K; Yamashita H; Nakaya K; Chihara T; Mori T; Tominaga M; Yabuuchi Y
    J Med Chem; 1993 Jul; 36(14):2011-7. PubMed ID: 8393113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protective effect of a vasopressin-1 selective antagonist, OPC-21268, against ethanol-induced damage of the rat gastric wall.
    Sugimoto I; Narimiya N; Odagiri M; Ohnishi A; Tanaka T
    Dig Dis Sci; 1999 Mar; 44(3):503-9. PubMed ID: 10080141
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human internal mammary artery responses to non-peptide vasopressin antagonists.
    Liu JJ; Phillips PA; Burrell LM; Buxton BB; Johnston CI
    Clin Exp Pharmacol Physiol; 1994 Feb; 21(2):121-4. PubMed ID: 8039263
    [TBL] [Abstract][Full Text] [Related]  

  • 18. OPC-21268, an orally effective, nonpeptide arginine vasopressin V1 receptor antagonist reduces vasogenic brain edema.
    Bemana I; Takahashi E; Nakamura T; Kuyama H; Nagao S
    Acta Neurochir Suppl; 1997; 70():194-7. PubMed ID: 9416320
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Organic osmolytes in rat renal inner medulla are modulated by vasopressin V1 and/or V2 antagonists.
    Nakanishi T; Yamauchi A; Nakahama H; Yamamura Y; Yamada Y; Orita Y; Fujiwara Y; Uyeda N; Takamitsu Y; Sugita M
    Am J Physiol; 1994 Jul; 267(1 Pt 2):F146-52. PubMed ID: 8048555
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of dexloxiglumide after administration of single and repeat oral escalating doses in healthy young males.
    Persiani S; D'Amato M; Makovec F; Tavares IA; Bishai PM; Rovati LC
    Int J Clin Pharmacol Ther; 2002 May; 40(5):198-206. PubMed ID: 12051571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.